UNCY FY2025 EPS Raised by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Brookline Capital Management boosted their FY2025 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, April 1st. Brookline Capital Management analyst K. Raja now expects that the company will post earnings of ($0.04) per share for the year, up from their prior estimate of ($0.15). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics' FY2025 earnings at ($0.04) EPS, FY2026 earnings at $1.52 EPS and FY2026 earnings at $1.52 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13).

Separately, HC Wainwright boosted their price target on Unicycive Therapeutics from $4.00 to $7.50 and gave the stock a "buy" rating in a research report on Tuesday, April 1st.

Unicycive Therapeutics Trading Up 7.4 %

Shares of Unicycive Therapeutics stock traded up $0.03 during trading hours on Friday, reaching $0.51. The stock had a trading volume of 357,828 shares, compared to its average volume of 1,436,661. Unicycive Therapeutics has a 1 year low of $0.20 and a 1 year high of $1.39. The firm has a market capitalization of $60.45 million, a price-to-earnings ratio of -0.52 and a beta of 2.15. The firm has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.57.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Unicycive Therapeutics in the third quarter valued at $29,000. Virtu Financial LLC raised its holdings in shares of Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after buying an additional 62,881 shares during the last quarter. Northern Trust Corp boosted its position in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock worth $46,000 after buying an additional 34,183 shares during the period. Geode Capital Management LLC grew its stake in shares of Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares in the last quarter. Finally, Acuta Capital Partners LLC increased its stake in Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.